EA200000349A1 - Способ лечения оппозиционного расстройства - Google Patents

Способ лечения оппозиционного расстройства

Info

Publication number
EA200000349A1
EA200000349A1 EA200000349A EA200000349A EA200000349A1 EA 200000349 A1 EA200000349 A1 EA 200000349A1 EA 200000349 A EA200000349 A EA 200000349A EA 200000349 A EA200000349 A EA 200000349A EA 200000349 A1 EA200000349 A1 EA 200000349A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
oppositional
disorders
oppositional disorders
treat
Prior art date
Application number
EA200000349A
Other languages
English (en)
Other versions
EA002689B1 (ru
Inventor
Джон Харрисон Хейлигенштейн
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200000349A1 publication Critical patent/EA200000349A1/ru
Publication of EA002689B1 publication Critical patent/EA002689B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Применение ингибиторов обратного поглощения норэпинефрина для лечения оппозиционного расстройства.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000349A 1997-09-23 1998-09-01 Способ лечения оппозиционного расстройства EA002689B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5962997P 1997-09-23 1997-09-23
PCT/US1998/018114 WO1999015176A1 (en) 1997-09-23 1998-09-01 Treatment of oppositional defiant disorder

Publications (2)

Publication Number Publication Date
EA200000349A1 true EA200000349A1 (ru) 2000-10-30
EA002689B1 EA002689B1 (ru) 2002-08-29

Family

ID=22024203

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000349A EA002689B1 (ru) 1997-09-23 1998-09-01 Способ лечения оппозиционного расстройства

Country Status (17)

Country Link
US (1) US6028070A (ru)
EP (1) EP0919236A1 (ru)
JP (1) JP2001517627A (ru)
KR (1) KR20010024218A (ru)
CN (1) CN1146412C (ru)
AU (1) AU740109B2 (ru)
BR (1) BR9812357A (ru)
CA (1) CA2304115A1 (ru)
EA (1) EA002689B1 (ru)
HU (1) HUP0003591A3 (ru)
IL (1) IL134716A0 (ru)
NO (1) NO20001458D0 (ru)
NZ (1) NZ502810A (ru)
PL (1) PL339426A1 (ru)
TR (1) TR200000755T2 (ru)
UA (1) UA56257C2 (ru)
WO (1) WO1999015176A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297346B6 (cs) 1998-04-09 2006-11-15 Pharmacia & Upjohn Company Pouzití reboxetinu pro výrobu léku k lécbe nervových poruch
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
EP1629843A3 (en) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Company LLC Reboxetine for treating chronic fatigue syndrome
DK1459750T3 (da) * 1999-07-01 2005-08-15 Pharmacia & Upjohn Co Llc (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
KR20020081403A (ko) * 2000-03-07 2002-10-26 일라이 릴리 앤드 캄파니 건선의 치료
WO2002078629A2 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
WO2003077897A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
WO2003092649A2 (en) * 2002-04-29 2003-11-13 Alza Corporation Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
CN1662511B (zh) * 2002-06-17 2010-06-09 辉瑞意大利公司 瑞波西汀的药物盐
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
PT1601349E (pt) * 2003-02-14 2008-10-27 Pf Medicament Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
EP1715856B1 (en) * 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetine formulations
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
JP2013510176A (ja) 2009-11-06 2013-03-21 ピエール ファーブル メディカモン （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
EP0537915B1 (en) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
CN1195287A (zh) * 1995-07-24 1998-10-07 伊莱利利公司 注意力涣散/多动症的治疗

Also Published As

Publication number Publication date
NO20001458L (no) 2000-03-21
TR200000755T2 (tr) 2000-09-21
EP0919236A1 (en) 1999-06-02
EA002689B1 (ru) 2002-08-29
CN1270520A (zh) 2000-10-18
WO1999015176A1 (en) 1999-04-01
AU9128298A (en) 1999-04-12
CA2304115A1 (en) 1999-04-01
NO20001458D0 (no) 2000-03-21
IL134716A0 (en) 2001-04-30
JP2001517627A (ja) 2001-10-09
AU740109B2 (en) 2001-11-01
CN1146412C (zh) 2004-04-21
KR20010024218A (ko) 2001-03-26
UA56257C2 (ru) 2003-05-15
HUP0003591A3 (en) 2002-02-28
NZ502810A (en) 2002-03-01
US6028070A (en) 2000-02-22
PL339426A1 (en) 2000-12-18
BR9812357A (pt) 2000-09-12
HUP0003591A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
EA200000349A1 (ru) Способ лечения оппозиционного расстройства
EA200000351A1 (ru) Лечение кондуктивных нарушений
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
EA200001244A1 (ru) Комбинационная терапия для лечения биполярных расстройств
EA199800667A1 (ru) Новые фенантридины
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
EA199900837A1 (ru) Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
EA199900324A1 (ru) Комбинированная терапия для лечения психозов
DE69737592D1 (de) Mittel gegen juckreiz
DE69905938T2 (de) Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
EA199900620A1 (ru) Фталазиноны
EA200200766A1 (ru) Замещенные арилпиразины
EA199800913A1 (ru) Кальцилитические соединения
ES2166110T3 (es) Agonistas no alostericos de gabaa para tratar trastornos del sueño.
DE69931957D1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns-erkrankungen
EA199700087A1 (ru) Способ ингибирования катепсина к
DE69808065T2 (de) Trisubstituierte phenyl derivate mit retinoid agonist, antagonist oder inversagonist biologischer aktivität
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
EA199800867A1 (ru) Соединения тетрагидробетакарболина
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
EA199800535A1 (ru) Способ лечения боли
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM